Pro-EU parties are set to hold onto two-thirds of the seats at the EU Parliament.Europe Politicsread more
The projected result comes shortly after Conservative Party leader Theresa May announced her resignation as prime minister on Friday morning.Europe Politicsread more
A Beijing decision to rapidly and sharply cut its excessive and unsustainable trade surplus with the U.S. would change for the better the bilateral relationship, writes...World Economyread more
Former Apple CEO John Sculley says this skill is vital to all great business leadership.Successread more
The U.S. and Japan will likely reach a trade settlement in the next six to nine months that will "give each side something to claim credit for," says Glen Fukushima, former...World Economyread more
Bitcoin surged more than 9% from the day before to hit its highest level in more than a year.Technologyread more
Stocks in Asia were mixed Monday morning as investors watched for developments from U.S. President Donald Trump's state visit to Japan as well as results from the European...Asia Marketsread more
Sources say the talks have picked up speed in recent days and could lead to an announcement regarding a merger or partnership by Monday.Autosread more
Biden had criticized Kim Jong Un as a "dictator" and a "tyrant" at a recent rally in Philadelphia. North Korean state media responded by calling Biden a "fool of low IQ" among...Politicsread more
Book income helped self-proclaimed socialist Bernie Sanders join the millionaire class, a group he has often criticized during his decades in politics.Politicsread more
Exit polls showed National Rally, a re-branding of Le Pen's National Front, beating Macron's party by just one seat.Europe Politicsread more
J.P. Morgan downgraded Pfizer shares to neutral from overweight on Tuesday, warning clients that the stock's rally will likely slow after climbing more than 22 percent this year.
"We clearly have seen a positive shift in Pfizer's narrative, which is now focused on the re-acceleration of the company's top and bottom line growth beyond 2020," J.P. Morgan's Chris Schott said in a note.
"However, with the company now trading in line with peers and the broader market, we see this improved core story as better reflected in valuation," Schott added. "And with further upside to shares likely tied to either additional pipeline success or positive new launch momentum (largely 2020+ events), we are moving to the sidelines."
Shares of Pfizer closed down 0.9 percent at $44.01 a share. J.P. Morgan stuck to its $46 price target on Pfizer. Investors have boosted Pfizer shares amid a broader sell-off in the market.